In the last trading session, 1.37 million Charles River Laboratories International Inc (NYSE:CRL) shares changed hands as the company’s beta touched 1.52. With the company’s per share price at $115.08 changed hands at $0.42 or 0.37% during last session, the market valuation stood at $5.65B. CRL’s last price was a discount, traded about -120.85% off its 52-week high of $254.15. The share price had its 52-week low at $91.86, which suggests the last value was 20.18% up since then. When we look at Charles River Laboratories International Inc’s average trading volume, we note the 10-day average is 2.17 million shares, with the 3-month average coming to 1.65 million.
Analysts gave the Charles River Laboratories International Inc (CRL) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.90. If we narrow down to specifics, the data shows that 0 out of 9 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 3 recommended CRL as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Charles River Laboratories International Inc’s EPS for the current quarter is expected to be 2.07.
Charles River Laboratories International Inc (NYSE:CRL) trade information
Instantly CRL was in green as seen at the end of in last trading. With action 12.09%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -37.66%, with the 5-day performance at 12.09% in the green. However, in the 30-day time frame, Charles River Laboratories International Inc (NYSE:CRL) is -27.19% down. Looking at the short shares, we see there were 3.03 million shares sold at short interest cover period of 1.42 days.
The consensus price target for the stock as assigned by Wall Street analysts is 290, meaning bulls need an upside of 60.32% from its current market value. According to analyst projections, CRL’s forecast low is 151 with 465 as the target high. To hit the forecast high, the stock’s price needs a -304.07% plunge from its current level, while the stock would need to soar -31.21% for it to hit the projected low.
Charles River Laboratories International Inc (CRL) estimates and forecasts
Year-over-year growth is forecast to reach -5.60% down from the last financial year.
Consensus estimates given by 12 financial analysts project the company’s revenue in the current quarter to hit an average of 941.94M. 12 analysts are of the opinion that Charles River Laboratories International Inc’s revenue for the current quarter will be 958.79M. The company’s revenue for the corresponding quarters a year ago was 1.01B and 1.03B respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -6.88%. The estimates for the next quarter sales put growth at -6.56%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -47.65%. The 2025 estimates are for Charles River Laboratories International Inc earnings to decrease by -9.75%, but the outlook for the next 5-year period is at 2.55% per year.
CRL Dividends
Charles River Laboratories International Inc is expected to release its next quarterly earnings report on 2025-Feb-18.
Charles River Laboratories International Inc (NYSE:CRL)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.88% of Charles River Laboratories International Inc shares while 111.25% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 112.24%. There are 111.25% institutions holding the Charles River Laboratories International Inc stock share, with VANGUARD GROUP INC the top institutional holder. As of 2024-06-30, the company held 11.8396% of the shares, roughly 6.1 million CRL shares worth $1.26 billion.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 9.8699% or 5.09 million shares worth $1.05 billion as of 2024-06-30.
Among Mutual Funds, the top two as of Jan 31, 2025 were VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 2.0 shares estimated at $230.06 million under it, the former controlled 4.07% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 3.25% of the shares, roughly 1.6 shares worth around $183.95 million.
